Galectin Therapeutics Inc’s recent filing unveils that its Director ELDRED KARY acquired Company’s shares for reported $1300.0 on Oct 23 ’24. In the deal valued at $2.60 per share,500 shares were bought. As a result of this transaction, ELDRED KARY now holds 50,213 shares worth roughly $52221.520000000004.
Then, FREEMAN KEVIN D bought 1,300 shares, generating $3,432 in total proceeds. Upon buying the shares at $2.64, the Director now owns 34,769 shares.
Before that, FREEMAN KEVIN D bought 5,000 shares. Galectin Therapeutics Inc shares valued at $13,500 were divested by the Director at a price of $2.70 per share. As a result of the transaction, FREEMAN KEVIN D now holds 80,000 shares, worth roughly $83200.0.
H.C. Wainwright reiterated its Galectin Therapeutics Inc [GALT] rating to a Buy in a research note published on August 13, 2020; the price target was $12. A number of analysts have revised their coverage, including B. Riley FBR’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering GALT and reiterated its “Buy” recommendation on December 07, 2017. H.C. Wainwright maintained its rating on November 28, 2017. It rated GALT as “a Buy”.
Price Performance Review of GALT
On Friday, Galectin Therapeutics Inc [NASDAQ:GALT] saw its stock fall -48.00% to $1.04. Over the last five days, the stock has lost -50.71%. Galectin Therapeutics Inc shares have fallen nearly -37.35% since the year began. Nevertheless, the stocks have fallen -39.18% over the past one year. While a 52-week high of $4.27 was reached on 04/12/24, a 52-week low of $1.55 was recorded on 12/20/24. SMA at 50 days reached $2.5120, while 200 days put it at $2.6428.
Levels Of Support And Resistance For GALT Stock
The 24-hour chart illustrates a support level at 0.6773, which if violated will result in even more drops to 0.3147. On the upside, there is a resistance level at 1.4513. A further resistance level may holdings at 1.8627. The Relative Strength Index (RSI) on the 14-day chart is 20.85, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.3476, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.93%. Stochastics %K at 17.33% indicates the stock is a buying.
How much short interest is there in Galectin Therapeutics Inc?
A steep rise in short interest was recorded in Galectin Therapeutics Inc stocks on 2024-10-31, growing by 0.14 million shares to a total of 5.52 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 5.38 million shares. There was a rise of 2.55%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 19, 2017 when ROTH Capital began covering the stock and recommended ‘”a Buy”‘ rating .
